• Maximilian Y Emmert, Robert W Hitchcock, and Simon P Hoerstrup.
• Swiss Center of Regenerative Medicine, Zurich, Switzerland; Division of Surgical Research, University Hospital Zurich, Zurich, Switzerland; Heart Center Zurich, University Hospital Zurich, Zurich, Switzerland.
• Adv. Drug Deliv. Rev. 2014 Apr 1; 69-70: 254-69.

AbstractIschemic Heart Disease (IHD) still represents the "Number One Killer" worldwide accounting for the death of numerous patients. However the capacity for self-regeneration of the adult heart is very limited and the loss of cardiomyocytes in the infarcted heart leads to continuous adverse cardiac-remodeling which often leads to heart-failure (HF). The concept of regenerative medicine comprising cell-based therapies, bio-engineering technologies and hybrid solutions has been proposed as a promising next-generation approach to address IHD and HF. Numerous strategies are under investigation evaluating the potential of regenerative medicine on the failing myocardium including classical cell-therapy concepts, three-dimensional culture techniques and tissue-engineering approaches. While most of these regenerative strategies have shown great potential in experimental studies, the translation into a clinical setting has either been limited or too rapid leaving many key questions unanswered. This review summarizes the current state-of-the-art, important challenges and future research directions as to regenerative approaches addressing IHD and resulting HF. Copyright © 2014 Elsevier B.V. All rights reserved.

25 keywords...

hide…